Seer, Inc. and Korea University Launch First Large-Scale Study to Identify Early-Onset Cancer Biomarkers Using Proteograph ONE Assay

Seer, Inc. and Korea University have launched a population-level study to identify blood-based cancer biomarkers in young adults using Seer's Proteograph ONE Assay, advanced mass spectrometry, and AI analytics. The study will analyze 20,000 plasma samples sourced from leading Korean cancer institutions, aiming to enhance early cancer detection and improve patient outcomes. Funded by the K-Health MIRAE program, this initiative marks the first large-scale plasma proteomics effort leveraging mass spectrometry and AI for this purpose, with the Proteograph ONE workflow processing over 1,000 samples per week.

Analysis

Seer, Inc. (SEER) has launched a significant population-level study with Korea University, targeting blood-based cancer biomarker identification in young adults through its newly introduced Proteograph ONE Assay, advanced mass spectrometry, and AI. This three-year initiative, funded by the K-Health MIRAE program, involves analyzing 20,000 plasma samples and is positioned as the first large-scale plasma proteomics study utilizing this combination of technologies for early cancer detection. Seer's Proteograph ONE workflow, capable of processing over 1,000 samples weekly and reportedly identifying up to 10 times more proteins than conventional mass spectrometry methods, is pivotal, alongside Thermo Fisher Scientific's (TMO) Orbitrap Astral mass spectrometer. While this collaboration could bolster Seer's reputation in innovative diagnostics, potential risks include the performance dependency on the new assay, reliance on external funding, and ethical data concerns. These operational considerations are amplified by recent insider trading data, which shows four sales by executives, including CEO Omid Farokhzad (41,731 shares for approximately $87,898) and President & CFO David R. Horn (10,310 shares for approximately $21,967), with no insider purchases in the last six months. Furthermore, institutional sentiment displays caution: 45 funds reduced their positions in SEER in the latest quarter compared to 20 increasing, with significant divestments from firms like Tang Capital Management (-41.0%, removing 900,000 shares) and Acuitas Investments (-100.0%, removing 424,414 shares), although Jacobs Levy Equity Management notably increased its stake by 124.5% (adding 201,491 shares). This creates a nuanced outlook, balancing technological potential against financial market signals and execution risks.

Key Decisions for Investors

• Investors should weigh the considerable long-term potential of Seer's Proteograph ONE technology and its application in the Korean cancer study against the cautionary signals from recent insider sales by senior executives and the net decrease in institutional ownership.
• Given the nascent stage of the Proteograph ONE Assay's large-scale deployment and the study's dependence on external funding, a cautious approach is advisable, potentially deferring new investments pending further validation of the technology's efficacy and market adoption.
• Closely monitor milestones from the Korea University study, commercial traction of the Proteograph ONE platform, and any changes in insider transaction patterns or institutional investor sentiment as key indicators for assessing Seer's investment viability.